NGO: Enforce smoking control act to protect underage Sarawakians from dangers of vaping
This has prompted TRADA president Joseph Janting to regard the issue as requiring immediate and focused attention by all relevant authorities.
Concurring with the Women, Childhood and Community Wellbeing Development' Ministry's commitment to find a solution on the matter, he pointed to existing legal framework, namely the Control of Smoking Products for Public Health Act 2024 (Act 852) which came into effect on Oct 1 last year.
'It is critical to recognise that in 2022 when the NHMS data was collected, there were no laws in place to regulate the vape industry,' recalled Janting.
'The difference today is that we now have Act 852, a dedicated regulatory framework for vape products which we must fully leverage to address the issue through firm and consistent enforcement.'
Janting further warned of recent reports which revealed the open sale of drug-laced vape products on social media and e-commerce platforms.
'Often disguised as flavoured vape and marketed to younger users, these illegal products highlight the urgent need for targeted enforcement rather than blanket bans,' he stressed.
'We're encouraged that the Ministry is taking proactive steps to address this issue, hence hoping to see strong enforcement against those who continue to sell to the underage.
'As a Sarawak-based NGO, TRADA stands ready to support efforts that safeguard our underaged from harm while ensuring regulations are fairly and effectively implemented.'
In a related development, TRADA also stressed the importance of directing enforcement efforts at irresponsible and illegal sellers who are knowingly violating the law by selling to the underage.
'Legal players are now subject to strict licensing, registration and compliance requirements under Act 852 but it's illegal, unregulated sellers who pose the real risk to underage individuals,' observed Janting.
'These bad actors must be dealt with seriously, with tough penalties to deter future violations.'
As long-term solution, TRADA is of the opinion that banning legal vape sales will only escalate the growth of underaged vape uses in Sarawak.
'The real danger lies in unregulated online platforms where illegal, drug-laced products are being sold with little oversight. Enforcement, not prohibition, is what will protect the underage,' insisted Janting.
'We urge all relevant agencies at both federal and state levels to work together to enforce Act 852 decisively to ensure that Sarawak's next generation is protected from harm through smart, targeted action.' – July 11, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Free Malaysia Today
7 hours ago
- Free Malaysia Today
20% of doctors wanting out of East Malaysia must ‘bite the bullet'
Health minister Dzulkefly Ahmad said transfer requests are being reviewed but all requests could not be accommodated without affecting services in Sabah and Sarawak. (Bernama pic) PETALING JAYA : About 20% of 600 medical officers who have applied to be transferred out from Sabah and Sarawak will have to 'bite the bullet' and stay put for now, says health minister Dzulkefly Ahmad. Dzulkefly said the ministry was reviewing the transfer requests but could ot accommodate every application without affecting health services in East Malaysia, which face a critical shortage of manpower. About 20% would not have their applications approved, he said. 'I know it's not ideal, but I've seen many specialists in Sabah who initially didn't want to go there. Now it's their 10th year and counting,' he told reporters today after launching a book on the Covid-19 pandemic and its effects on Malaysia. Dzulkefly said not all placements can rely on arrangements for mutual transfers. On Thursday, the Dewan Rakyat was told there were 650 vacancies for permanent posts in Sarawak, but only seven medical officers have opted to take up these posts. Dzulkefly encouraged doctors, especially those posted as couples, to consider the long-term benefits of serving in East Malaysia. Asked what steps the ministry was taking to solve the high number of transfer requests, the minister said Putrajaya was exploring offering better incentive schemes to retain doctors in Sabah and Sarawak. 'We are trying to see what other incentives can be offered. We know this is an issue we can't completely avoid, but we will do our level best to manage it.' No queue jumping in Rakan KKM Dzulkefly gave an assurance there would be no queue jumping in the Rakan KKM programme, which offers 'premium economy' services at selected public hospitals. Under the programme, specialists can offer paid elective services, with the income reinvested to improve the health service. 'This isn't about jumping queues for emergency cases. It's about giving people an option for elective procedures while retaining top talent,' he said. He said a briefing on the programme would be held as some information on the initiative had been misinterpreted. Two weeks ago, the Malaysian Medical Association had questioned if wealthier patients would get faster access to health services, and urged the ministry to clarify the programme and if it would strain an already overstretched health service.
New Straits Times
2 days ago
- New Straits Times
UN agency: Almost a third of Gazans 'not eating for days'
ROME: Almost a third of people in Gaza are "not eating for days", the United Nations food aid agency told AFP on Friday, saying the crisis has reached "new and astonishing levels of desperation." The Rome-based World Food Programme had previously warned of a "critical risk of famine" in war-ravaged Gaza, over which international condemnation of Israel's actions has been growing. "Nearly one person in three is not eating for days. Malnutrition is surging with 90,000 women and children in urgent need of treatment," a WFP statement said. It said that 470,000 people are expected to face "catastrophic hunger" – the most critical category under the UN's Integrated Food Security Phase classification – between May and September this year. "Food aid is the only way for people to access any food as food prices are through the roof," the WFP said. "People are dying from lack of humanitarian assistance." Aid groups have warned of surging numbers of malnourished children in Gaza, which Israel placed under an aid blockade in March amid its war with Hamas.
Malaysian Reserve
2 days ago
- Malaysian Reserve
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)
